Monday, July 18, 2016 @ 10:00am Eastern Time
Toll Free:
888-452-4023
Israel Investors:
1 80 924 5906
International:
719-457-1512
Conference ID:
5455376
Webcast:
http://public.viavid.com/index.php?id=120422
Replays, available through August 1, 2016
Toll Free:
877-870-5176
International:
858-384-5517
Conference ID:
5455376
About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwntechnology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwnhas been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company's website at www.brainstorm-cell.com.
Contacts
Media:
Uri Yablonka, COO
Chief Operating Officer
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188
uri@brainstorm-cell.com
Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979
mrice@lifesciadvisors.com